APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

BRAF Kinase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global BRAF Kinase Inhibitors Industry Growth and Trends Forecast to 2032

Report ID 173972370122 December 202573 pages

Choose your research edition.

Industry ResearchBRAF Kinase Inhibitors Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal BRAF Kinase Inhibitors Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal BRAF Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal BRAF Kinase Inhibitors Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal BRAF Kinase Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global BRAF Kinase Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for BRAF Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for BRAF Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for BRAF Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of BRAF Kinase Inhibitors include Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd. and Array BioPharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global BRAF Kinase Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The BRAF Kinase Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (L) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global BRAF Kinase Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to BRAF Kinase Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global BRAF Kinase Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

BRAF Kinase Inhibitors Market by Company

Novartis AG

Bayer AG

F. Hoffmann-La Roche Ltd.

Array BioPharma Inc.

BRAF Kinase Inhibitors Segment by Type

Vemurafenib

Sorafenib

Encorafenib

Dabrafenib

BRAF Kinase Inhibitors Segment by Application

Clinic

Hospital

Medical Research Institute

Other

BRAF Kinase Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global BRAF Kinase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of BRAF Kinase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of BRAF Kinase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of BRAF Kinase Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of BRAF Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vemurafenib Table 2. Major Company of Sorafenib Table 3. Major Company of Encorafenib Table 4. Major Company of Dabrafenib Table 5. Global BRAF Kinase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global BRAF Kinase Inhibitors Sales by Type (2021-2026) & (L) Table 7. Global BRAF Kinase Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 8. Global BRAF Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 9. Global BRAF Kinase Inhibitors Sales Market Share in Value by Type (2021-2026) Table 10. Global BRAF Kinase Inhibitors Price by Type (2021-2026) & (US$/L) Table 11. Global BRAF Kinase Inhibitors Sales by Type (2027-2032) & (L) Table 12. Global BRAF Kinase Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 13. Global BRAF Kinase Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 14. Global BRAF Kinase Inhibitors Sales Market Share in Value by Type (2027-2032) Table 15. Global BRAF Kinase Inhibitors Price by Type (2027-2032) & (US$/L) Table 16. North America BRAF Kinase Inhibitors Sales by Type (2021-2026) & (L) Table 17. North America BRAF Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 18. Europe BRAF Kinase Inhibitors Sales by Type (2021-2026) & (L) Table 19. Europe BRAF Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific BRAF Kinase Inhibitors Sales by Type (2021-2026) & (L) Table 21. Asia-Pacific BRAF Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America BRAF Kinase Inhibitors Sales by Type (2021-2026) & (L) Table 23. Latin America BRAF Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa BRAF Kinase Inhibitors Sales by Type (2021-2026) & (L) Table 25. Middle East and Africa BRAF Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 26. BRAF Kinase Inhibitors Industry Trends Table 27. BRAF Kinase Inhibitors Industry Drivers Table 28. BRAF Kinase Inhibitors Industry Opportunities and Challenges Table 29. BRAF Kinase Inhibitors Industry Restraints Table 30. Global BRAF Kinase Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global BRAF Kinase Inhibitors Revenue Market Share by Company (2021-2026) Table 32. Global BRAF Kinase Inhibitors Sales by Company (2021-2026) & (L) Table 33. Global BRAF Kinase Inhibitors Sales Share by Company (2021-2026) Table 34. Global BRAF Kinase Inhibitors Market Price by Company (2021-2026) & (US$/L) Table 35. Global BRAF Kinase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global BRAF Kinase Inhibitors Major Company Production Sites and Headquarters Table 37. Global BRAF Kinase Inhibitors Company, Product Type & Application Table 38. Global BRAF Kinase Inhibitors Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global BRAF Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global BRAF Kinase Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global BRAF Kinase Inhibitors Sales by Region (2021-2026) & (L) Table 43. Global BRAF Kinase Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 44. Global BRAF Kinase Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 45. Global BRAF Kinase Inhibitors Sales Market Share in Value by Region (2021-2026) Table 46. Global BRAF Kinase Inhibitors Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 47. Global BRAF Kinase Inhibitors Sales by Region (2027-2032) & (L) Table 48. Global BRAF Kinase Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 49. Global BRAF Kinase Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 50. Global BRAF Kinase Inhibitors Sales Market Share in Value by Region (2027-2032) Table 51. Global BRAF Kinase Inhibitors Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2027-2032) Table 52. Global BRAF Kinase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global BRAF Kinase Inhibitors Sales by Application (2021-2026) & (L) Table 54. Global BRAF Kinase Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 55. Global BRAF Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 56. Global BRAF Kinase Inhibitors Sales Market Share in Value by Application (2021-2026) Table 57. Global BRAF Kinase Inhibitors Price by Application (2021-2026) & (US$/L) Table 58. Global BRAF Kinase Inhibitors Sales by Application (2027-2032) & (L) Table 59. Global BRAF Kinase Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 60. Global BRAF Kinase Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 61. Global BRAF Kinase Inhibitors Sales Market Share in Value by Application (2027-2032) Table 62. Global BRAF Kinase Inhibitors Price by Application (2027-2032) & (US$/L) Table 63. North America BRAF Kinase Inhibitors Sales by Application (2021-2026) & (L) Table 64. North America BRAF Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 65. Europe BRAF Kinase Inhibitors Sales by Application (2021-2026) & (L) Table 66. Europe BRAF Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific BRAF Kinase Inhibitors Sales by Application (2021-2026) & (L) Table 68. Asia-Pacific BRAF Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America BRAF Kinase Inhibitors Sales by Application (2021-2026) & (L) Table 70. Latin America BRAF Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa BRAF Kinase Inhibitors Sales by Application (2021-2026) & (L) Table 72. Middle East and Africa BRAF Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG BRAF Kinase Inhibitors Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 76. Novartis AG BRAF Kinase Inhibitors Product Portfolio Table 77. Novartis AG Recent Development Table 78. Bayer AG Company Information Table 79. Bayer AG Business Overview Table 80. Bayer AG BRAF Kinase Inhibitors Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 81. Bayer AG BRAF Kinase Inhibitors Product Portfolio Table 82. Bayer AG Recent Development Table 83. F. Hoffmann-La Roche Ltd. Company Information Table 84. F. Hoffmann-La Roche Ltd. Business Overview Table 85. F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 86. F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Product Portfolio Table 87. F. Hoffmann-La Roche Ltd. Recent Development Table 88. Array BioPharma Inc. Company Information Table 89. Array BioPharma Inc. Business Overview Table 90. Array BioPharma Inc. BRAF Kinase Inhibitors Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 91. Array BioPharma Inc. BRAF Kinase Inhibitors Product Portfolio Table 92. Array BioPharma Inc. Recent Development Table 93. North America BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 94. North America BRAF Kinase Inhibitors Sales by Country (2021-2026) & (L) Table 95. North America BRAF Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 96. North America BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032) & (L) Table 97. North America BRAF Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 98. North America BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America BRAF Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 100. North America BRAF Kinase Inhibitors Market Share by Country (2021-2026) Table 101. North America BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America BRAF Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 103. Europe BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 104. Europe BRAF Kinase Inhibitors Sales by Country (2021-2026) & (L) Table 105. Europe BRAF Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 106. Europe BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032) & (L) Table 107. Europe BRAF Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 108. Europe BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Europe BRAF Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 110. Europe BRAF Kinase Inhibitors Market Share by Country (2021-2026) Table 111. Europe BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Europe BRAF Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 113. Asia-Pacific BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 114. Asia-Pacific BRAF Kinase Inhibitors Sales by Country (2021-2026) & (L) Table 115. Asia-Pacific BRAF Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 116. Asia-Pacific BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032) & (L) Table 117. Asia-Pacific BRAF Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific BRAF Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific BRAF Kinase Inhibitors Market Share by Country (2021-2026) Table 121. Asia-Pacific BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific BRAF Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 123. Latin America BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 124. Latin America BRAF Kinase Inhibitors Sales by Country (2021-2026) & (L) Table 125. Latin America BRAF Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 126. Latin America BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032) & (L) Table 127. Latin America BRAF Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 128. Latin America BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Latin America BRAF Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 130. Latin America BRAF Kinase Inhibitors Market Share by Country (2021-2026) Table 131. Latin America BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Latin America BRAF Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 133. Middle East and Africa BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (L): 2021 VS 2025 VS 2032 Table 134. Middle East and Africa BRAF Kinase Inhibitors Sales by Country (2021-2026) & (L) Table 135. Middle East and Africa BRAF Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 136. Middle East and Africa BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032) & (L) Table 137. Middle East and Africa BRAF Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa BRAF Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East and Africa BRAF Kinase Inhibitors Market Share by Country (2021-2026) Table 141. Middle East and Africa BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa BRAF Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. BRAF Kinase Inhibitors Distributors List Table 146. BRAF Kinase Inhibitors Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. BRAF Kinase Inhibitors Image Figure 2. Global BRAF Kinase Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global BRAF Kinase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global BRAF Kinase Inhibitors Sales (2021-2032) & (L) Figure 5. Vemurafenib Image Figure 6. Global Vemurafenib Sales YoY Growth (2021-2032) & (L) Figure 7. Sorafenib Image Figure 8. Global Sorafenib Sales YoY Growth (2021-2032) & (L) Figure 9. Encorafenib Image Figure 10. Global Encorafenib Sales YoY Growth (2021-2032) & (L) Figure 11. Dabrafenib Image Figure 12. Global Dabrafenib Sales YoY Growth (2021-2032) & (L) Figure 13. Global BRAF Kinase Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global BRAF Kinase Inhibitors Market Share by Type 2025 VS 2032 Figure 15. North America BRAF Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. North America BRAF Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Europe BRAF Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Europe BRAF Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific BRAF Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific BRAF Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Latin America BRAF Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Latin America BRAF Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa BRAF Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa BRAF Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 BRAF Kinase Inhibitors Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (L) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (L) Figure 31. Medical Research Institute Image Figure 32. Global Medical Research Institute Sales YoY Growth (2021-2032) & (L) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (L) Figure 35. Global BRAF Kinase Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global BRAF Kinase Inhibitors Market Share by Application 2025 VS 2032 Figure 37. North America BRAF Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. North America BRAF Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Europe BRAF Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Europe BRAF Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific BRAF Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific BRAF Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Latin America BRAF Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Latin America BRAF Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa BRAF Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa BRAF Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 47. North America BRAF Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 48. North America BRAF Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America BRAF Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America BRAF Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe BRAF Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 52. Europe BRAF Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe BRAF Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe BRAF Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific BRAF Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 56. Asia-Pacific BRAF Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific BRAF Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific BRAF Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America BRAF Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 60. Latin America BRAF Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America BRAF Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America BRAF Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa BRAF Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (L) Figure 64. Middle East and Africa BRAF Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa BRAF Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa BRAF Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. BRAF Kinase Inhibitors Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. BRAF Kinase Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Vemurafenib
  • Sorafenib
  • Encorafenib
  • Dabrafenib
Applications
  • Clinic
  • Hospital
  • Medical Research Institute
  • Other
Companies covered
  • Novartis AG
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Array BioPharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global BRAF Kinase Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global BRAF Kinase Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 BRAF Kinase Inhibitors Market by Type
  6. 1.3.1 Vemurafenib
  7. 1.3.2 Sorafenib
  8. 1.3.3 Encorafenib
  9. 1.3.4 Dabrafenib
  10. 1.4 Global BRAF Kinase Inhibitors Market Size by Type
  11. 1.4.1 Global BRAF Kinase Inhibitors Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global BRAF Kinase Inhibitors Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global BRAF Kinase Inhibitors Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America BRAF Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe BRAF Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific BRAF Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America BRAF Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa BRAF Kinase Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 BRAF Kinase Inhibitors Industry Trends
  2. 2.2 BRAF Kinase Inhibitors Industry Drivers
  3. 2.3 BRAF Kinase Inhibitors Industry Opportunities and Challenges
  4. 2.4 BRAF Kinase Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by BRAF Kinase Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by BRAF Kinase Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by BRAF Kinase Inhibitors Price (2021-2026)
  4. 3.4 Global BRAF Kinase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global BRAF Kinase Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global BRAF Kinase Inhibitors Company, Product Type & Application
  7. 3.7 Global BRAF Kinase Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global BRAF Kinase Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 BRAF Kinase Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 BRAF Kinase Inhibitors Tier 1, Tier 2, and Tier 3
4 BRAF Kinase Inhibitors Regional Status and Outlook
  1. 4.1 Global BRAF Kinase Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global BRAF Kinase Inhibitors Historic Market Size by Region
  3. 4.2.1 Global BRAF Kinase Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global BRAF Kinase Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global BRAF Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global BRAF Kinase Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global BRAF Kinase Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global BRAF Kinase Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global BRAF Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 BRAF Kinase Inhibitors by Application
  1. 5.1 BRAF Kinase Inhibitors Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Medical Research Institute
  5. 5.1.4 Other
  6. 5.2 Global BRAF Kinase Inhibitors Market Size by Application
  7. 5.2.1 Global BRAF Kinase Inhibitors Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global BRAF Kinase Inhibitors Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global BRAF Kinase Inhibitors Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America BRAF Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe BRAF Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific BRAF Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America BRAF Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa BRAF Kinase Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG BRAF Kinase Inhibitors Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Bayer AG
  8. 6.2.1 Bayer AG Company Information
  9. 6.2.2 Bayer AG Business Overview
  10. 6.2.3 Bayer AG BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer AG BRAF Kinase Inhibitors Product Portfolio
  12. 6.2.5 Bayer AG Recent Developments
  13. 6.3 F. Hoffmann-La Roche Ltd.
  14. 6.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 6.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 6.3.3 F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Product Portfolio
  18. 6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 6.4 Array BioPharma Inc.
  20. 6.4.1 Array BioPharma Inc. Company Information
  21. 6.4.2 Array BioPharma Inc. Business Overview
  22. 6.4.3 Array BioPharma Inc. BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Array BioPharma Inc. BRAF Kinase Inhibitors Product Portfolio
  24. 6.4.5 Array BioPharma Inc. Recent Developments
7 North America by Country
  1. 7.1 North America BRAF Kinase Inhibitors Sales by Country
  2. 7.1.1 North America BRAF Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America BRAF Kinase Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America BRAF Kinase Inhibitors Market Size by Country
  6. 7.2.1 North America BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America BRAF Kinase Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe BRAF Kinase Inhibitors Sales by Country
  2. 8.1.1 Europe BRAF Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe BRAF Kinase Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe BRAF Kinase Inhibitors Market Size by Country
  6. 8.2.1 Europe BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe BRAF Kinase Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific BRAF Kinase Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific BRAF Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific BRAF Kinase Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific BRAF Kinase Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific BRAF Kinase Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America BRAF Kinase Inhibitors Sales by Country
  2. 10.1.1 South America BRAF Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America BRAF Kinase Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America BRAF Kinase Inhibitors Market Size by Country
  6. 10.2.1 South America BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America BRAF Kinase Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa BRAF Kinase Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa BRAF Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa BRAF Kinase Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa BRAF Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa BRAF Kinase Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa BRAF Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa BRAF Kinase Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa BRAF Kinase Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 BRAF Kinase Inhibitors Value Chain Analysis
  2. 12.1.1 BRAF Kinase Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 BRAF Kinase Inhibitors Production Mode & Process
  7. 12.2 BRAF Kinase Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 BRAF Kinase Inhibitors Distributors
  10. 12.2.3 BRAF Kinase Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst